Alder Biopharmaceuticals - Top 20 VC deals of 2008

Alder Biosciences, Fiercebiotech's top venture capital deals of 2008Company: Alder Biopharmaceuticals
Based: Bothell, WA
Amount: $40.2 million

Investors: TPG Growth, Delphi Ventures, Ventures West Management, Sevin Rosen Funds, H.I.G. Capital, WRF Capital

Scoop: Alder started 2008 on a good foot. The company secured a $40.2 million third round in January to support development of its lead antibody therapeutic ALD518 through multiple proof-of-concept trials. Unlike many other biopharma companies, Alder actually boosted its staff from 34 to about 50. The new employees are working on antibody manufacturing and clinical development.

Alder Biopharmaceuticals - Top 20 VC deals of 2008

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.